3,425 Shares in Natera, Inc. $NTRA Bought by Independent Financial Group LLC

Independent Financial Group LLC acquired a new stake in shares of Natera, Inc. (NASDAQ:NTRA) in the first quarter, HoldingsChannel.com reports. The firm acquired 3,425 shares of the medical research company’s stock, valued at approximately $685,000.

A number of other institutional investors also recently bought and sold shares of the company. Integrated Wealth Concepts LLC increased its position in shares of Natera by 6.6% during the 1st quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock valued at $221,000 after purchasing an additional 96 shares during the last quarter. NewEdge Advisors LLC boosted its holdings in shares of Natera by 68.3% in the first quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock worth $644,000 after buying an additional 1,847 shares during the last quarter. Focus Partners Wealth boosted its holdings in shares of Natera by 8.6% in the first quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock worth $847,000 after buying an additional 474 shares during the last quarter. Sivia Capital Partners LLC bought a new stake in Natera during the second quarter valued at approximately $298,000. Finally, WINTON GROUP Ltd bought a new stake in Natera during the second quarter valued at approximately $558,000. Institutional investors own 99.90% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on NTRA. Wolfe Research began coverage on shares of Natera in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $260.00 price target on the stock. BTIG Research set a $275.00 price objective on Natera and gave the stock a “buy” rating in a research note on Wednesday, June 24th. William Blair assumed coverage on Natera in a report on Tuesday, April 14th. They issued an “outperform” rating on the stock. Robert W. Baird set a $265.00 target price on Natera in a research report on Friday, May 8th. Finally, Royal Bank Of Canada assumed coverage on Natera in a research report on Thursday, June 11th. They set an “outperform” rating and a $275.00 target price on the stock. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $267.83.

Natera Trading Down 1.1%

NASDAQ NTRA opened at $264.22 on Thursday. Natera, Inc. has a 12 month low of $131.81 and a 12 month high of $288.04. The stock has a market cap of $37.84 billion, a price-to-earnings ratio of -162.10 and a beta of 1.51. The company’s 50 day moving average is $237.88 and its two-hundred day moving average is $221.08.

Insider Transactions at Natera

In related news, Director Gail Boxer Marcus sold 11,000 shares of Natera stock in a transaction on Friday, June 5th. The shares were sold at an average price of $217.21, for a total transaction of $2,389,310.00. Following the transaction, the director owned 6,183 shares in the company, valued at approximately $1,343,009.43. The trade was a 64.02% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Rowan E. Chapman sold 2,964 shares of the company’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $216.78, for a total transaction of $642,535.92. Following the completion of the transaction, the director directly owned 3,124 shares of the company’s stock, valued at $677,220.72. This represents a 48.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 178,872 shares of company stock valued at $39,627,696. Company insiders own 5.05% of the company’s stock.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.